Traditional Chinese medicine composition for treating chemotherapy gastrointestinal dysfunction of gastric cancer patient and application of traditional Chinese medicine composition

Abstract

The invention discloses a traditional Chinese medicine composition for treating gastrointestinal dysfunction during chemotherapy of gastric cancer. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 9-15 parts of inula flower, 9-15 parts of bamboo shavings, 3-9 parts of flos caryophylli, 6-15 parts of kaki calyx, 6-15 parts of lignum dalbergiae odoriferae, 15-20 parts of betel nut, 15-20 parts of pericarpium arecae, 15-20 parts of combined spicebush root, 20-30 parts of semen raphani, 15-20 parts of immature bitter orange and 9-15 parts of prepared rhubarb. The traditional Chinese medicine composition is prepared into the acupoint application. In addition, the invention further discloses application of the traditional Chinese medicine composition, the traditional Chinese medicine composition is ground into fine powder, the fine powder is blended into paste with a solvent, or the mixture is prepared into ointment, pills or cakes, or the traditional Chinese medicine decoction is decocted into ointment, or the medicine powder is dispersed on the plaster, and then the plaster is directly applied to the Shenque acupoint, the Zusanli acupoints on the two sides and the Neiguan acupoints on the two sides. The traditional Chinese medicine composition has a good treatment effect on gastrointestinal dysfunction of gastric cancer patients during chemotherapy.

Description

Technical Field

[0001] The invention relates to a traditional Chinese medicine composition for treating gastrointestinal dysfunction in gastric cancer patients during chemotherapy and application thereof. Background Art

[0003] The main treatment for patients with advanced gastric cancer is a combination of chemotherapy, targeted therapy, and immunotherapy. Although targeted and immunotherapy have achieved good results in gastric cancer in recent years, these treatments often need to be combined with chemotherapy. Therefore, chemotherapy remains the cornerstone of treatment for gastric cancer patients.

[0004] Chemotherapy often causes gastrointestinal dysfunction such as nausea, vomiting, and constipation. The stomach is an important digestive and absorptive organ in the human body, and patients with gastric cancer often experience symptoms such as bloating, stomach pain, nausea, and vomiting. The digestive dysfunction of gastric cancer patients becomes more serious after chemotherapy, which in turn affects the patient's diet and nutrient absorption, often resulting in the inability to carry out chemotherapy normally.

[0005] The treatment of gastric cancer with traditional Chinese medicine is characterized by syndrome differentiation and treatment, and the treatment method is mainly oral decoction. However, gastric cancer patients during chemotherapy have gastrointestinal dysfunction and often find it difficult to take decoction orally. Therefore, the advantages of external treatment of traditional Chinese medicine are gradually emerging. Compared with oral medication, external application of traditional Chinese medicine can significantly reduce the gastrointestinal burden of patients, and patients have good compliance.

[0006] In summary, currently, most traditional Chinese medicines for treating chemotherapy-induced gastrointestinal dysfunction in gastric cancer patients are oral decoctions, and there are no reports in the literature on external application of traditional Chinese medicine combinations for treating gastrointestinal dysfunction in patients with advanced gastric cancer. Summary of the invention

[0007] In view of the above-mentioned deficiencies in the prior art, according to an embodiment of the present invention, it is hoped to provide a Chinese medicine composition for treating gastrointestinal dysfunction during chemotherapy for gastric cancer, and propose the use of the Chinese medicine composition.

[0008] According to the embodiments, the present invention provides a traditional Chinese medicine composition for treating gastrointestinal dysfunction during chemotherapy for gastric cancer, wherein the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 9-15 parts of Inula flower, 9-15 parts of Rhizoma Zingiberis, 3-9 parts of Caryophyllus caryophyllus, 6-15 parts of Persimmon calyx, 6-15 parts of Dalbergia odorifera, 15-20 parts of Areca catechu, 15-20 parts of Citrus grandis peel, 15-20 parts of Linderae serrata, 20-30 parts of Radish seed, 15-20 parts of Citrus aurantium, and 9-15 parts of processed Rhubarb.

[0009] As a preferred example, the Chinese medicine composition is made of the following raw materials in parts by weight: 9 parts of Inula flower, 9 parts of Rhizoma Zingiberis, 6 parts of Caryophyllus caryophyllus, 9 parts of Persimmon calyx, 9 parts of Dalbergia odorifera, 15 parts of Areca catechu, 15 parts of Citrus grandis peel, 15 parts of Linderae strychnifolia, 25 parts of Radish seeds, 15 parts of Citrus aurantium, and 9 parts of processed Rhubarb.

[0010] Furthermore, the Chinese medicine composition is an external medicine.

[0011] Furthermore, the external medicine is an acupoint application.

[0012] Acupoint application is a non-invasive acupoint therapy that is based on the theory of meridians in traditional Chinese medicine. The medicine is ground into fine powder, mixed with solvent into a paste, or made into ointments, pills or cakes, or the Chinese medicine decoction is boiled into a paste, or the medicine powder is sprinkled on a plaster, and then directly applied to the acupoints to treat diseases. It works through multiple links and multiple channels. In essence, it is a composite treatment method that integrates meridians, acupoints and medicines.

[0013] According to the embodiment, the present invention adopts Chinese medicine external application to treat gastric cancer patients with gastrointestinal dysfunction during chemotherapy, and acupoints Shenque, Neiguan and Zusanli are selected. Shenque acupoint is a key acupoint of Ren Meridian, which is the key to the circulation of essence, qi, spirit and blood. It has the effects of strengthening the spleen and stomach, warming yang and consolidating deficiency, and nourishing the essence and consolidating the foundation. Hiccups, abdominal pain and bloating can be improved by methods such as acupoint application. Neiguan acupoint belongs to the hand Jueyin pericardium meridian. This acupoint is the intersection of the eight meridians and Yinwei. Yinwei is a disease in the viscera. This acupoint is good at treating visceral diseases, and is mainly used to treat stomachache, vomiting, hiccups and other symptoms. Zusanli is one of the main acupoints of the stomach meridian of foot yangming, which has the effects of drying spleen dampness and generating stomach qi, and is mainly used to treat digestive dysfunction such as stomachache, vomiting, hiccups, bloating, constipation and so on.

[0014] The following examples will prove that the acupoint application of the Chinese medicine composition of the present invention (hereinafter also referred to as the anti-reverse and abdominal plaster) adopts a self-made prescription (9g of Inula Flos, 9g of Rhizoma Zingiberis, 6g of Clove, 9g of Persimmon Calyx, 9g of Dalbergia Odorifera, 15g of Areca Nut, 15g of Radix Atractylodes Macrocephalae, 15g of Radix Linderae, 25g of Radish Seed, 15g of Fructus Aurantii Immaturus, and 9g of processed Rhubarb), in which Inula Flos, Rhizoma Zingiberis, Clove, and Persimmon Calyx can reduce Qi and resolve phlegm, reduce anti-reverse and stop hiccups; Dalbergia Odorifera can invigorate blood circulation and relieve pain, reduce Qi and avoid filth; Areca Nut, Radix Atractylodes Macrocephalae, Fructus Aurantii Immaturus, remove phlegm and eliminate abdominal distension; Radish Seed and processed Rhubarb can digest food and eliminate bloating, and purge to attack accumulation; the whole prescription has the effects of reducing anti-reverse and stopping hiccups, promoting Qi and removing stagnation, and purge to attack accumulation, and has a good therapeutic effect on gastrointestinal dysfunction in patients with gastric cancer during chemotherapy. DETAILED DESCRIPTION

[0015] The present invention will be further described below in conjunction with specific embodiments. It should be understood that these embodiments are only intended to illustrate the present invention and are not intended to limit the scope of the present invention. In addition, it should be understood that after reading the content of the present invention, those skilled in the art may make various changes or modifications to the present invention, and these equivalent forms fall within the scope limited by the appended claims of the application equally.

[0016] Example 1

[0017] 9g of Inula flower, 9g of Rhizoma Zingiberis, 6g of Caryophyllus, 9g of Persimmon calyx, 9g of Dalbergia odorifera, 15g of Areca catechu, 15g of Phellodendron chinense, 15g of Linderae truncatula, 25g of Radish seed, 15g of Citrus aurantium, 9g of processed Rhubarb. Grind the above medicines into powder, mix them evenly, and sterilize them. Mix the powder with appropriate amount of Vaseline evenly, and make pills with a diameter of about 1cm on a pill making machine. Package them for later use.

[0018] Example 2

[0019] 12g of Inula flower, 9g of Rhizoma Anemarrhenae, 6g of Clove, 6g of Persimmon calyx, 6g of Dalbergia odorifera, 20g of Areca catechu, 15g of Phellodendron chinense, 15g of Linderae strychnifolia, 20g of Radish seed, 15g of Citrus aurantium, 9g of processed Rhubarb. Grind the above medicines into powder, mix them evenly, and sterilize them. Mix the powder with appropriate amount of Vaseline evenly, and make pills with a diameter of about 1cm on a pill making machine. Package them for later use.

[0020] Example 3

[0021] Grind the above medicines into powder, mix them evenly, and sterilize them. Mix the powder with appropriate amount of vaseline evenly, and make pills with a diameter of about 1 cm on a pill-making machine, and package them for later use.

[0022] Example 4

[0023] 12g of Inula flower, 12g of Rhizoma Zingiberis, 3g of Clove, 6g of Persimmon calyx, 9g of Dalbergia odorifera, 15g of Areca catechu, 15g of Phellodendron chinense, 15g of Linderae truncatula, 20g of Radish seed, 15g of Citrus aurantium, 9g of processed Rhubarb. Grind the above medicines into powder, mix them evenly, and sterilize them. Stir the powder and appropriate amount of Vaseline evenly, and make pills with a diameter of about 1cm on a pill making machine. Package them for later use.

[0024] Example 5

[0025] Grind the above medicines into powder, mix them evenly, and sterilize them. Mix the powder with appropriate amount of vaseline evenly, and make pills with a diameter of about 1 cm on a pill-making machine, and package them for later use.

[0026] Example 6

[0027] 9g of Inula flower, 9g of Rhizoma Zingiberis, 9g of Clove, 9g of Persimmon calyx, 12g of Dalbergia odorifera, 15g of Areca catechu, 15g of Citrus grandis peel, 20g of Linderae strychnifolia, 30g of Radish seed, 20g of Citrus aurantium, 15g of processed Rhubarb. Grind the above medicines into powder, mix them evenly, and sterilize them. Stir the powder and appropriate amount of Vaseline evenly, make pills with a diameter of about 1cm on a pill making machine, and package them for later use.

[0028] Example 7 - Analysis of the clinical efficacy of the Jiangni Tongfu patch

[0029] 1 Research data and methods

[0030] 1.1 Case data

[0031] The included cases were 72 patients with advanced gastric cancer who received chemotherapy in the Oncology Ward of Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine from January 2021 to December 2023. All patients were informed of this study and voluntarily participated and cooperated with clinical observation. All patients were divided into two groups according to the random number table method, namely the treatment group (Jiangni Tongfu Paste Treatment) (n=38) and the control group (n=34). There was no statistically significant difference in general data between the two groups (P>0.05)

[0032] 1.2 Diagnostic criteria

[0033] TNM staging of gastric cancer: According to the American Cancer Society revised AJCC / UICC staging manual, 8th edition. The diagnostic criteria for gastrointestinal dysfunction refer to the "Guidelines for Clinical Research of New Chinese Medicines" and "Modern Chinese Medicine Oncology", with fullness as the main symptom, combined with relevant symptoms related to gastrointestinal function to determine the diagnostic criteria.

[0034] 1.3 Inclusion criteria

[0035] (1) Patients diagnosed with advanced gastric cancer by pathology and receiving chemotherapy;

[0036] (2) 18 ≤ ≤ 70 years old, regardless of gender;

[0037] (3) expected survival time ≥ 6 months, performance status score (ECOG) ≤ 2;

[0038] (4) Agree to accept follow-up and Jiangni Tongfu plaster treatment; have complete follow-up and clinical related medical records; and voluntarily sign the informed consent form.

[0039] 1.4 Exclusion criteria

[0040] (1) Patients who are pregnant, breastfeeding or planning to become pregnant;

[0041] (2) Those who are allergic to the drugs used in this study or their components;

[0042] (3) Patients with severe heart, brain, liver, kidney disease or mental illness;

[0043] (4) patients with a history of multiple tumors;

[0044] (5) The presence of severe or difficult-to-control infection;

[0045] 1.5 Elimination criteria

[0046] (1) Those with poor compliance or voluntarily withdrawing from this study will be considered dropouts;

[0047] (2) Serious adverse events occurred and were included in the statistics of adverse reactions;

[0048] (3) Those who dropped out due to ineffectiveness were included in the efficacy analysis;

[0049] (4) The included patients did not take the prescribed medication, had insufficient course of treatment, or had incomplete case reports

[0050] 2 Research Methods

[0051] 2.1 Treatment methods

[0052] Control group: According to the guidance of the 2020 NCCN (National Comprehensive Cancer Network) palliative care guidelines and the "New Guidelines for the Diagnosis and Treatment of Common Malignant Tumors (Cancer Pain Control and Palliative Care Volume)", symptomatic treatments such as granisetron, metoclopramide, omeprazole, and lactulose were used according to the patient's clinical symptoms, but no immune function regulating drugs were used.

[0053] Treatment group: On the basis of the treatment of the control group, weigh the Chinese medicine Inula 9g, Zingiberis 9g, Clove 6g, Persimmon 9g, Dalbergia odorifera 9g, Areca 15g, Pitaya 15g, Lindera 15g, Radish 25g, Citrus aurantium 15g, Rhubarb 9g, grind the above drugs into powder, mix evenly, sterilize, mix the powder and appropriate amount of vaseline evenly, make pills with a diameter of about 1cm on a pill making machine, and package for standby use. On the day of chemotherapy, after routine disinfection of acupoints (Shenque point, bilateral Zusanli points, bilateral Neiguan points), apply the pills on the acupoints and seal and fix them with desensitizing tape. Apply once a day for 8 to 12 hours. Continuous application for 1 week is a course of treatment.

[0054] 2.2 Observation indicators

[0055] ① TCM symptom score

[0056] According to the efficacy evaluation criteria of the "Guidelines for Clinical Research of New Chinese Medicines", the gastrointestinal function symptom scores of the two groups of patients after one course of treatment were observed. According to the principle of graded quantification, the main symptoms include epigastric distension, loss of appetite, nausea and vomiting, and the secondary symptoms include laziness, shortness of breath, vomiting of clear water, noisy stomach, belching and acid reflux, constipation, loose stools, dry stools, etc. The main symptoms are assigned 0 points, 2 points, 4 points, and 6 points according to absence, mild, moderate, and severe; the secondary symptoms are assigned 0 points, 1 point, 2 points, and 3 points according to absence, mild, moderate, and severe. The criteria for judging the efficacy of TCM syndromes were formulated with reference to the Guiding Principles for Clinical Research of New Chinese Medicines: clinical cure: symptoms and signs disappear, efficacy index ≥ 90%; marked effect: symptoms and signs basically disappear, 60% ≤ efficacy index < 90%; effective: symptoms and signs are alleviated, 30% ≤ efficacy index < 60%; ineffective: symptoms and signs are not alleviated, or even aggravated, efficacy index < 90%. The efficacy index was calculated based on the main symptom scores before and after treatment, using the nimodipine symptom score method. Formula: efficacy index = [(total symptom score before treatment - total symptom score after treatment) ÷ total symptom score before treatment] × 100%.

[0057] ②Quality of life

[0058] The quality of life score (QOL) of cancer patients is a commonly used scale in my country to assess the quality of life of cancer patients. It has 12 items in total, each of which is divided into 5 levels, with scores ranging from 1 to 5. The full score for quality of life is 60 points, good is 51-60 points, better is 41-50 points, average is 31-40 points, poor is 21-30 points, and extremely poor is <20 points.

[0059] 3 Statistical analysis

[0060] The chi-square test and t-test were used to compare the mean values ​​of the data samples between the two groups, expressed as (x±s), and P<0.05 was considered to be different and statistically significant.

[0061] 4 Research results

[0062] 4.1 Comparison of TCM symptom scores before and after treatment

[0063] Comparing before and after treatment, Jiangni Tongfu Paste can effectively improve gastrointestinal symptoms (nausea and vomiting, constipation, diarrhea), and the difference is statistically significant (P < 0.01). Compared with the control group, the improvement effect of the treatment group is more obvious and better than that of the control group (P < 0.05).

[0064] Table 1. Comparison of TCM symptom scores before and after treatment

[0065] Group Number of cases Before treatment After treatment Treatment Group 38 23.89±0.77 <![CDATA[19.53±0.58 *# ]]> Control group 34 23.76±0.84 21.29±0.67

[0066] Note: Compared with before treatment, *P<0.01, comparison between groups after treatment # P<0.05.

[0067] 4.2 Comparison of quality of life scale before and after treatment.

[0068] Comparing before and after treatment, Jiangni Tongfu Paste can significantly improve the patients' quality of life, and the difference is statistically significant (P < 0.01). Compared with the control group, the improvement effect of the treatment group is more obvious and better than that of the control group (P < 0.05).

[0069] Table 2. Comparison of quality of life scores (QOL) before and after treatment

[0070] Group Number of cases Before treatment After treatment Treatment Group 38 41.47±0.71 <![CDATA[46.08±0.61 *# ]]> Control group 34 41.18±0.78 43.97±0.82

[0071] Note: Compared with before treatment, * P<0.01, comparison between groups after treatment # P<0.05.

[0072] Example 8 (Animal Experiment)

[0073] 1 Materials and methods

[0074] 1.1 Drugs and reagents

[0075] Preparation of the Chinese medicine composition of the present invention: Prepare according to Example 1.

[0076] Preparation of the Chinese medicine composition for the control group: 2g of Inula flower, 2g of Rhizoma Zingiberis, 1g of Clove, 2g of Persimmon Calyx, 2g of Dalbergia odorifera, 3g of Areca catechu, 3g of Phellodendron chinense, 3g of Linderae strychnifolia, 5g of Radish Seed, 3g of Immature Citrus aurantium, and 2g of processed Rhubarb are prepared by weight. Grind the above drugs into powder, mix them evenly, and sterilize them. Stir the powder and an appropriate amount of vaseline evenly, make pills with a diameter of about 1 cm on a pill making machine, and package them for later use.

[0077] Main reagents: fluorouracil injection (Shanghai Xudong Haipu Pharmaceutical Co., Ltd.); normal saline (Shanghai Yansheng Industrial Co., Ltd.); N-nitrosodiethylamine (Shanghai Puzhen Biotechnology Co., Ltd.); gastrin (GAS), rat motilin (MTL), vasoactive intestinal peptide (VIP) ELISA detection kit (provided by Nanjing Jiancheng Technology Co., Ltd.).

[0078] 1.2 Animals

[0079] 60 SPF SD rats, weighing 80-100 g, half male and half female, were provided by Shanghai Slake Experimental Animal Service Co., Ltd.

[0080] 1.3 Main instruments

[0081] Electronic balance (Mettler Toledo, Switzerland); centrifuge (Beijing Medical Centrifuge Factory); syringe (BD Medical Devices Company)

[0082] 2 Methods and Results

[0083] 2.1 Animal model establishment and grouping

[0084] Sixty rats were randomly divided into 4 groups, namely blank group, model group, application group and control group, with 15 rats in each group. The blank group was fed normally, and the remaining 3 groups were modeled. After fasting for 24 hours, they were given N-nitrosodiethylamine (DENA) 2.8 mg / kg for 80 consecutive days to model gastric cancer. After successful modeling, chemotherapy was performed and fluorouracil injection was given at a dose of 20 mg / kg intraperitoneally, 0.2 ml each time, once a day, for 7 consecutive days; during chemotherapy, the acupoints of the rats were located according to the "Experimental Acupuncture" combined with the rat acupoint map for modeling rats. According to the analogy principle, the Shenque, Neiguan, Zusanli and other acupoints of the modeling rats were depilated, and the residual hair was washed off, and then they were divided into groups for treatment.

[0085] 2.2 Grouped Dosing

[0086] Blank group: Normal feeding without any treatment.

[0087] Model group: After the end of fluorouracil administration, the mice were gavaged with normal saline every day.

[0088] Application group: The rats were tied to a mouse board using the Chinese medicine composition of the present invention (prepared according to Example 1), acupoints were located and hair was clipped, and the prepared application cakes were fixed on the acupoints with desensitizing tape. The rats were tied for 6 hours, and the drug was administered continuously for 7 days, and physiological saline was administered orally.

[0089] Control group: The rats were tied to a mouse board using the aforementioned Chinese medicine composition for the control group. After acupuncture points were located and hair was clipped, the prepared control patch cakes were fixed on the acupuncture points with desensitizing tape. The rats were tied for 6 hours, given medication for 7 consecutive days, and administrated with normal saline.

[0090] 2.3 Specimen collection and processing

[0091] After the experiment, the rats were fasted for 24 hours and anesthetized with 20% urethane 4 mL / kg intraperitoneally. Blood was collected from the abdominal aorta and kept at room temperature for 2-3 hours. The blood was centrifuged at 4°C, 3000 r / min, for 15 minutes. The supernatant was collected and stored at -20°C for testing.

[0092] 2.4 Evaluation index detection

[0093] (1) General condition observation: Carefully observe the rats’ mental state, posture, fur color, activity, reactivity to restraint, color of the palpebral mucosa, feces, and other general conditions every day.

[0094] (2) ELISA kits were used to detect the levels of plasma gastrin (GAS), motilin (MTL) and vasoactive intestinal polypeptide (VIP) in rats.

[0095] (3) Gastric emptying and small intestinal propulsion experiments were performed using the semi-solid rice paste method to calculate the gastric emptying rate and small intestinal propulsion rate of rats. (Xing Jianfeng, Feng Weiyi, Hou Jiayu. Study on the experimental methods of gastric emptying and small intestinal propulsion in mice. Journal of Beijing University of Chinese Medicine 2003; 26: 50-52)

[0096] 2.5 Statistical analysis

[0097] SPSS16.0 software was used for processing. All measurement data were expressed as sample content (n) and mean ± SD. All data were tested for normality and homogeneity of variance. If normality was satisfied, one-way ANOVA was used for multiple groups of measurement data. LSD method was selected when variance was equal, and Dunnett T3 method was selected when variance was unequal; rank sum test was selected when normality was not satisfied. P < 0.05 was considered to be significantly different.

[0098] 2.6 Results

[0099] 2.6.1 Observation of general condition of rats in each group

[0100] Before the experiment, the rats in each group were in good mental state, active, shiny fur, spherical feces and moderate dryness. After modeling, the rats in the model group lay still and moved less, looked tired, had dull hair, drooping whiskers, huddled or dormant in corners, and had loose stools. The mental state of the rats in the application group was better than that in the model group, the rats were more active, their hair was neat, and their feces were dry. There was no significant difference between the control group and the model group. The weight of the rats in each group after the administration is shown in Table 3. Compared with the blank group, the body weight of the rats in the model group was significantly lower than that in the blank group (P < 0.001); compared with the model group, the body weight of the rats in the application group was significantly higher than that in the model group (P < 0.05), and there was no significant difference in the body weight of the control group (P > 0.05).

[0101] Table 3. Body weight changes of rats in each group

[0102] Group Body weight (end of administration) / g Blank Group 182.85±2.11 Model Group <![CDATA[147.38±4.47 1) ]]> Application group <![CDATA[163.36±2.88 1)2)3) ]]> Control group <![CDATA[149.05±5.23 1) ]]>

[0103] Note: Compared with the blank group 1) (P<0.001); compared with the model group 2) (P<0.05), compared with the control group 3) (P<0.05).

[0104] 2.6.2 Plasma gastrin (GAS), motilin (MTL) and vasoactive intestinal polypeptide (VIP) levels in rats of each group

[0105] The levels of GAS, MTL and VIP in rat plasma are shown in Table 4. Compared with the blank group, the levels of GAS and MTL in the model group were significantly decreased (P < 0.05, P < 0.01), and the level of VIP was significantly increased (P < 0.05). Compared with the model group, the levels of GAS and MTL in the plasma of the rats in the application group were significantly increased, and the level of VIP was significantly decreased (P < 0.05). Compared with the model group, there were no significant differences in the levels of GAS, MTL and VIP in the plasma of the rats in the control group.

[0106] Table 4. Contents of GAS, MTL and VIP in rats of each group

[0107] Group GAS / (pg / mL) MTL / (pg / mL) VIP / (pg / mL) Blank Group 61.60±2.38 118.11±4.46 31.81±1.70 Model Group <![CDATA[49.01±2.05 1) ]]> <![CDATA[95.13±4.42 3) ]]> <![CDATA[36.53±1.29 1) ]]> Patching group <![CDATA[55.60±2.16 2) ]]> <![CDATA[107.12±3.59 2) ]]> <![CDATA[32.27±1.58 2) ]]> Control group 49.67±1.89 97.47±4.32 35.87±1.27

[0108] Note: Compared with the blank group 1) (P<0.05) 3) (P<0.01); compared with the model group 2) (P<0.05).

[0109] 2.6.3 Comparison of gastrointestinal motility in rats of each group

[0110] The comparison results of gastrointestinal motility of rats in each group are shown in Table 5. Compared with the blank group, the gastric emptying rate and small intestinal propulsion rate of the model group were significantly reduced (P < 0.001); compared with the model group, the gastric emptying rate of the application group was significantly increased (P < 0.005); the small intestinal propulsion rate was significantly increased (P < 0.01). Compared with the model group, there was no significant difference in the gastric emptying rate and small intestinal propulsion rate of rats in the control group.

[0111] Table 5. Comparison of gastrointestinal motility in rats

[0112] Group Gastric emptying rate / % Small intestinal propulsion rate / % Blank Group 71.07±1.35 72.33±2.18 Model Group <![CDATA[59.13±1.62 1) ]]> <![CDATA[61.01±1.90 1) ]]> Patching group <![CDATA[67.20±1.95 2) ]]> <![CDATA[68.67±2.25 3) ]]> Control group 60.53±1.70 62.07±2.24

[0113] Note: Compared with the blank group 1) (P<0.001); compared with the model group 2) (P<0.005), 3) (P<0.01).

[0114] In conclusion, the Chinese medicine composition of the present invention in the application group has the effect of improving the gastrointestinal dysfunction of gastric cancer chemotherapy-induced rats to varying degrees.

Claims

1. A Chinese medicine composition for treating gastrointestinal dysfunction during chemotherapy for gastric cancer, characterized in that: The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 9-15 parts of Inula flower, 9-15 parts of Rhizoma Zingiberis, 3-9 parts of Caryophyllus caryophyllus, 6-15 parts of Persimmon calyx, 6-15 parts of Dalbergia odorifera, 15-20 parts of Areca catechu, 15-20 parts of Citrus grandis peel, 15-20 parts of Linderae truncatula, 20-30 parts of Radish seeds, 15-20 parts of Citrus aurantium, and 9-15 parts of processed rhubarb.

2. The Chinese medicine composition according to claim 1, characterized in that: The weight portions of the raw materials are respectively: 9 parts of Inula flower, 9 parts of Rhizoma Zingiberis, 6 parts of Caryophyllus caryophyllus, 9 parts of Persimmon calyx, 9 parts of Dalbergia odorifera, 15 parts of Areca catechu, 15 parts of Rhizoma Citri Reticulatae, 15 parts of Linderae strychnifoliae, 25 parts of Radish seeds, 15 parts of Fructus Aurantii Immaturus and 9 parts of processed Rhubarb.

3. The Chinese medicine composition according to claim 1 or 2, characterized in that: The Chinese medicine composition is prepared into an external medicine.

4. The Chinese medicine composition according to claim 3, characterized in that: The external medicine is acupoint application.

5. Use of the Chinese medicine composition according to claim 1 or 2 in the preparation of a medicament for treating gastrointestinal dysfunction during chemotherapy of gastric cancer.

6. The method according to claim 5, characterized in that: The Chinese medicine composition is ground into fine powder, adjusted into a paste with a solvent, or made into an ointment, pills or cakes, or the Chinese medicine decoction is boiled into a paste, or the medicine powder is sprinkled on a plaster, and then directly applied to the Shenque point, bilateral Zusanli points, and bilateral Neiguan points.